source
- Akeso details survival win for its PD-1xVEGF drug versus KeytrudaAkeso and Summit Therapeutics claimed a key win over Keytruda at the start of September, and are now spelling out that survival data. They hope it will add to the trove of results supporting the ...Endpoints · 37m ago↗ source
- AstraZeneca's breast cancer pill camizestrant fails to improve progression-free survival in pivotal SERENA-4 trialAstraZeneca announced that its oral estrogen receptor degrader camizestrant, marketed as Etcamah, did not meet its primary endpoint in the phase III SERENA-4 trial. The study evaluated camizestran…